Trends in inflammatory breast carcinoma incidence and survival: The Surveillance, Epidemiology, and End Results Program at the National Cancer Institute

被引:450
作者
Hance, KW
Anderson, WF
Devesa, SS
Young, HA
Levine, PH
机构
[1] NCI, Canc Prevent Fellowship Program, Div Canc Prevent, NIH, Bethesda, MD 20892 USA
[2] George Washington Univ, Sch Publ Hlth & Hlth Serv, Dept Epidemiol & Biostat, Washington, DC USA
[3] NCI, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA
[4] George Washington Univ, Inst Canc, Washington, DC USA
来源
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE | 2005年 / 97卷 / 13期
关键词
D O I
10.1093/jnci/dji172
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Inflammatory breast carcinoma (IBC) appears to be a clinicopathologic entity distinct from noninflammatory locally advanced breast cancer (LABC). We examined incidence and, survival trends for IBC in Surveillance, Epidemiology, and End Results (SEER).Program data with a case definition designed to capture many of its unique clinical and pathologic characteristics. Methods: We analyzed breast cancer cases diagnosed in the SEER 9 Registries (n = 180 224), between 1988 and 2000. Breast cancer cases were categorized using SEER's "Extent of Disease" codes in combination with International Classification of Diseases for Oncology morphology code 8530/3 and classified as IBC (n = 3648), LABC (n = 3636), and non-T4 breast cancer (n = 172 940). We compared changes in incidence rates over 3-year intervals by breast cancer subtype and race using SEER*Stat. Survival differences by breast cancer subtype and race were assessed using Kaplan-Meier curves and log-rank statistics. All statistical tests were two-sided. Results: Between 1988 and 1990 and 1997 and 1999, IBC incidence rates (per 100000 womanyears) increased from 2.0 to 2.5 (P <.001), whereas those for LABC declined (2.5 to 2.0, P =.0025), as did those for non-T4 breast cancer (108 to 101, P =.0084). IBC incidence rates were statistically significantly higher in black women (3.1) than in white women (2.2) during the study period (P <.001). Women diagnosed with IBC had statistically significantly poorer survival than women with either LABC or non-T4 breast cancer (log-rank test, P <.001). Median survival of women with IBC (2.9 years) was statistically significantly shorter than that of women with LABC (6.4 years; P <.0001) or non-T4 breast cancer (> 10 years, P <.0001). Black women with IBC or LABC had poorer survival than white women with IBC or LABC, respectively (log-rank test, P <.001). Conclusions: Throughout the 1990s, IBC incidence rose, and survival improved modestly. Substantial racial differences were noted in age at diagnosis, age-specific incidence rates, and survival outcomes.
引用
收藏
页码:966 / 975
页数:10
相关论文
共 52 条
[1]   Inflammatory breast carcinoma:: Pathological or clinical entity? [J].
Amparo, RS ;
Angel, CDM ;
Ana, LH ;
Antonio, LC ;
Vicente, MS ;
Carlos, FM ;
Vicente, GP .
BREAST CANCER RESEARCH AND TREATMENT, 2000, 64 (03) :269-273
[2]   Tumor variants by hormone receptor expression in white patients with node-negative breast cancer from the surveillance, epidemiology, and end results database [J].
Anderson, WF ;
Chu, KC ;
Chatterjee, N ;
Brawley, O ;
Brinton, LA .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (01) :18-27
[3]  
Anderson WF, 2004, CANCER EPIDEM BIOMAR, V13, P1128
[4]   Inflammatory breast carcinoma: The sphinx of breast cancer research - In Reply [J].
Anderson, WF ;
Chu, KC ;
Chang, S .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (02) :383-383
[5]   Inflammatory breast carcinoma and noninflammatory locally advanced breast carcinoma: Distinct clinicopathologic entities? [J].
Anderson, WF ;
Chu, KC ;
Chang, S .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (12) :2254-2259
[6]   Estrogen receptor breast cancer phenotypes in the surveillance, epidemiology, and end results database [J].
Anderson, WF ;
Chatterjee, N ;
Ershler, WB ;
Brawley, OW .
BREAST CANCER RESEARCH AND TREATMENT, 2002, 76 (01) :27-36
[7]  
[Anonymous], DESIGN EXPT
[8]  
[Anonymous], [No title captured]
[9]  
BARBER KW, 1961, SURG GYNECOL OBSTET, V112, P406
[10]  
BONNIER P, 1992, European Journal of Gynaecological Oncology, V13, P7